Status: Recruiting
ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer
This prospective, multicenter, single-arm phase II interventional study evaluates whether longitudinal circulating tumor DNA (ctDNA) monitoring can guide neoadjuvant immunotherapy and surgical decision-making in dMMR/MSI-H colon cancer. Participants with ctDNA clearance proceed to curative surgery, whereas those with persistent ctDNA positivity escalate to combined PD-1 and CTLA-4 inhibitor therapy.
Participants needed: 23
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Fudan UniversityUpdated: Sep 25, 2026Locations: 1
Eligibility criteria
Written informed consent obtained before any study-related procedures. [+6]
Prior treatment with a PD-1 inhibitor, CTLA-4 inhibitor, or other immunotherapy. [+11]